|
|
|
|
Vol. 57, Issue 2, 278-287, February 2000
-Adrenergic Receptor Signaling in
G
q-Mediated Cardiac Hypertrophy and Ventricular
Dysfunction
Departments of Medicine (G.W.D., G.W., S.B.L.) and Pharmacology
(G.W.D., N.M.T., A.Y., S.B.L.), University of Cincinnati College of
Medicine, Cincinnati, Ohio.
Targeted cardiac overexpression of the
-subunit of the
heterotrimeric G protein Gq in transgenic mice evokes
hypertrophy and depressed stimulation of cardiac inotropy and
chronotropy by
-adrenergic receptor (
AR) agonists in vivo, which
is a hallmark of many forms of experimental and human heart failure.
The molecular basis of this
AR dysfunction was explored in
transgenic mice overexpressing G
q ~5-fold over
background. Isoproterenol-stimulated adenylyl cyclase activities in
myocardial membranes were significantly depressed in G
q
mice compared with nontransgenic controls (19.7 ± 2.6 versus
43.7 ± 5.6 pmol/min/mg) without a decrease in
AR expression
levels. Functional coupling of both
AR subtypes was impaired.
Similarly, in whole-cell patch-clamp studies,
AR stimulation of
L-type Ca2+ channel currents was depressed ~75% in the
G
q mice. Cardiac
AR from these mice showed decreased
formation of the active high-affinity conformation
(RH = 29% versus 62% for nontransgenic
littermates), confirming a receptor-Gs-coupling defect. Of
the three candidate kinases that might impose this uncoupling by
receptor phosphorylation (protein kinase A,
AR kinase, protein
kinase C), only protein kinase C activity was elevated in
G
q mouse hearts. Type V adenylyl cyclase was decreased
~45% in these mice, consistent with decreased basal, NaF, and
forskolin-stimulated enzyme activities. Although cellular
Gs levels were unaltered, Gi2 and
Gi3 were increased in G
q mice. Pertussis
toxin treatment of isolated G
q myocytes resulted in an
improvement in
AR, but not that of forskolin or NaF, stimulation of
adenylyl cyclase. Thus three distinct mechanisms contribute to impaired
AR function by in vivo Gq signaling cross-talk in
myocytes. Because many elements of hypertrophy and/or failure in
cellular and animal models can be initiated by increased
G
q signaling, the current work may be broadly applicable
to interfaces whereby modification of heart failure might be considered.
This article has been cited by other articles:
![]() |
B. J. Wilson, R. Harada, L. LeDuy, M. D. Hollenberg, and A. Nepveu CUX1 Transcription Factor Is a Downstream Effector of the Proteinase-activated Receptor 2 (PAR2) J. Biol. Chem., January 2, 2009; 284(1): 36 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Endoh Novel signalling cascade for cardiac hypertrophy activation by uncoupling and internalization of {beta}1-adrenoceptors Cardiovasc Res, April 1, 2008; 78(1): 5 - 7. [Full Text] [PDF] |
||||
![]() |
S. Salim, K. M. Standifer, and D. C. Eikenburg Extracellular Signal-Regulated Kinase 1/2-Mediated Transcriptional Regulation of G-Protein-Coupled Receptor Kinase 3 Expression in Neuronal Cells J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 51 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Galvez, E. W. Brunskill, Y. Marreez, B. J. Benner, K. M. Regula, L. A. Kirschenbaum, and G. W. Dorn II Distinct Pathways Regulate Proapoptotic Nix and BNip3 in Cardiac Stress J. Biol. Chem., January 20, 2006; 281(3): 1442 - 1448. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Penela, C. Murga, C. Ribas, A. S. Tutor, S. Peregrin, and F. Mayor Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease Cardiovasc Res, January 1, 2006; 69(1): 46 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Iaccarino, E. Barbato, E. Cipolletta, V. De Amicis, K. B. Margulies, D. Leosco, B. Trimarco, and W. J. Koch Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure Eur. Heart J., September 1, 2005; 26(17): 1752 - 1758. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Balasubramanian, Y. Xia, E. Freinkman, and M. Gerstein Sequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphisms Nucleic Acids Res., March 22, 2005; 33(5): 1710 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tachibana, S. V. Naga Prasad, R. J. Lefkowitz, W. J. Koch, and H. A. Rockman Level of {beta}-Adrenergic Receptor Kinase 1 Inhibition Determines Degree of Cardiac Dysfunction After Chronic Pressure Overload-Induced Heart Failure Circulation, February 8, 2005; 111(5): 591 - 597. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tang, M. H. Gao, D. M. Roth, T. Guo, and H. K. Hammond Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1906 - H1912. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Dent, N. S. Dhalla, and P. S. Tappia Phospholipase C gene expression, protein content, and activities in cardiac hypertrophy and heart failure due to volume overload Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H719 - H727. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Hahn, Y. Marreez, A. Odley, A. Sterbling, M. G. Yussman, K. C. Hilty, I. Bodi, S. B. Liggett, A. Schwartz, and G. W. Dorn II Protein Kinase C{alpha} Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy Circ. Res., November 28, 2003; 93(11): 1111 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kerkela, M. Ilves, S. Pikkarainen, H. Tokola, J. Ronkainen, O. Vuolteenaho, J. Leppaluoto, and H. Ruskoaho Identification of PKCalpha Isoform-Specific Effects in Cardiac Myocytes Using Antisense Phosphorothioate Oligonucleotides Mol. Pharmacol., December 1, 2002; 62(6): 1482 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Keys, E. A. Greene, W. J. Koch, and A. D. Eckhart Gq-Coupled Receptor Agonists Mediate Cardiac Hypertrophy Via the Vasculature Hypertension, November 1, 2002; 40(5): 660 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huke, V. Prasad, M. L. Nieman, K. J. Nattamai, I. L. Grupp, J. N. Lorenz, and M. Periasamy Altered dose response to beta -agonists in SERCA1a-expressing hearts ex vivo and in vivo Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H958 - H965. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Feldman Adenylyl Cyclase: A New Target for Heart Failure Therapeutics Circulation, April 23, 2002; 105(16): 1876 - 1878. [Full Text] [PDF] |
||||
![]() |
S. F. Steinberg G protein-coupled receptor kinases: gotta real kure for heart failure? J. Am. Coll. Cardiol., August 1, 2001; 38(2): 541 - 545. [Full Text] [PDF] |
||||
![]() |
V. B. Serikov, N. N. Petrashevskaya, A. M. Canning, and A. Schwartz Reduction of [Ca2+]i Restores Uncoupled {beta}-Adrenergic Signaling in Isolated Perfused Transgenic Mouse Hearts Circ. Res., January 19, 2001; 88(1): 9 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mochly-Rosen, G. Wu, H. Hahn, H. Osinska, T. Liron, J. N. Lorenz, A. Yatani, J. Robbins, and G. W. Dorn II Cardiotrophic Effects of Protein Kinase C {epsilon} : Analysis by In Vivo Modulation of PKC{epsilon} Translocation Circ. Res., June 9, 2000; 86(11): 1173 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wu, T. Toyokawa, H. Hahn, and G. W. Dorn II epsilon Protein Kinase C in Pathological Myocardial Hypertrophy. ANALYSIS BY COMBINED TRANSGENIC EXPRESSION OF TRANSLOCATION MODIFIERS AND Galpha q J. Biol. Chem., September 22, 2000; 275(39): 29927 - 29930. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Small, K. M. Brown, S. L. Forbes, and S. B. Liggett Modification of the beta 2-Adrenergic Receptor to Engineer a Receptor-Effector Complex for Gene Therapy J. Biol. Chem., August 17, 2001; 276(34): 31596 - 31601. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wu, M. G. Yussman, T. J. Barrett, H. S. Hahn, H. Osinska, G. M. Hilliard, X. Wang, T. Toyokawa, A. Yatani, R. A. Lynch, et al. Increased Myocardial Rab GTPase Expression: A Consequence and Cause of Cardiomyopathy Circ. Res., December 7, 2001; 89(12): 1130 - 1137. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Roth, H. Bayat, J. D. Drumm, M. H. Gao, J. S. Swaney, A. Ander, and H. K. Hammond Adenylyl Cyclase Increases Survival in Cardiomyopathy Circulation, April 23, 2002; 105(16): 1989 - 1994. [Abstract] [Full Text] [PDF] |
||||